EDITORIAL

2453 Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy?
Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A

REVIEW

2459 Pathogenesis and clinical spectrum of primary sclerosing cholangitis
Gidwaney NG, Pawa S, Das KM

2470 Biliary tract cancer stem cells - translational options and challenges
Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T

MINIREVIEWS

2483 Potential role of nutraceutical compounds in inflammatory bowel disease
Larussa T, Imeneo M, Luzza F

2493 Unusual gastric tumors and tumor-like lesions: Radiological with pathological correlation and literature review
Lin YM, Chiu NC, Li AFY, Liu CA, Chou YH, Chiu YY

2505 New progress in roles of nitric oxide during hepatic ischemia reperfusion injury
Zhang YQ, Ding N, Zeng YF, Xiang YY, Yang MW, Hong FF, Yang SL

ORIGINAL ARTICLE

Basic Study

2511 Berberine displays antitumor activity in esophageal cancer cells in vitro
Jiang SX, Qi B, Yao WJ, Gu CW, Wei XF, Zhao Y, Liu YZ, Zhao BS

Case Control Study

2519 Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer

2527 Colors of vegetables and fruits and the risks of colorectal cancer
Lee J, Shin A, Oh JH, Kim J
Retrospective Cohort Study
2539 Impact of vitamin D on the hospitalization rate of Crohn's disease patients seen at a tertiary care center
Venkata KVR, Arora SS, Xie FL, Malik TA

2545 Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Retrospective Study
2556 Laparoscopic approach to suspected T1 and T2 gallbladder carcinoma
Ome Y, Hashida K, Yokota M, Nagahisa Y, Okabe M, Kawamoto K

2566 Clinical characteristics of peptic ulcer perforation in Korea
Yang YJ, Bang CS, Shin SP, Park TY, Suk KT, Baik GH, Kim DJ

2575 Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer

Clinical Trials Study
2585 PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma

2592 Endothelial progenitor cells in peripheral blood may serve as a biological marker to predict severe acute pancreatitis
Ha XQ, Song YJ, Zhao HB, Ta WW, Gao HW, Feng QS, Dong JZ, Deng ZY, Fan HY, Peng JH, Yang ZH, Zhao Y

2601 Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder
Wu ZC, Xiong L, Wang LX, Miao XY, Liu ZR, Li DQ, Zou Q, Liu KJ, Zhao H, Yang ZL

Observational Study
2613 Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis

2625 Upper gastrointestinal cancer burden in Hebei Province, China: A population-based study
Li DJ, Liang D, Song GH, Li YW, Wen DG, Jin J, He YT
World Journal of Gastroenterology
Volume 23 Number 14 April 14, 2017

Contents

ABOUT COVER
Editorial board member of World Journal of Gastroenterology, Vicente Lorenzo-Zuniga, MD, PhD, Associate Professor, Chief Doctor, Staff Physician, Endoscopy Unit, Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol/CIBERReh, Badalona 08916, Spain

AIMS AND SCOPE
World Journal of Gastroenterology (WJG), print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. WJG was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The WJG Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of WJG is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. WJG is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING
World Journal of Gastroenterology (WJG) is now indexed in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports® released by Thomson Reuters (ISI) cites the 2015 impact factor for WJG as 2.787 (5-year impact factor: 2.848), ranking WJG as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF
I-IX Editorial Board

EDITORS FOR THIS ISSUE

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28046, Spain
Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden
Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 9001 F. Seventh St, Long Beach, CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at http://www.wjgnet.com/1007-9327/editorialboard.htm

EDITORIAL OFFICE
Jim Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk

PUBLISHER
Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk

Copyright © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/bpg/general/204

ONLINE SUBMISSION
http://www.f6publishing.com

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Cai-Hong Wang
Proofing Editor-in-Chief: Lian-Sheng Ma
Responsible Science Editor: Yuan Qi
Proofing Editorial Office Director: Jin-Lei Wang

http://www.wjgnet.com
New progress in roles of nitric oxide during hepatic ischemia reperfusion injury

Ya-Qi Zhang, Ning Ding, Yong-Fen Zeng, Yuan-Yuan Xiang, Mei-Wen Yang, Fen-Fang Hong, Shu-Long Yang

Yao Qi Zhang, Ning Ding, Yong-Fen Zeng, Yuan-Yuan Xiang, Mei-Wen Yang, Shu-Long Yang, Department of Physiology, Basic Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, China

Fen-Fang Hong, Medical Experimental Teaching Center, Jiangxi Medical College, Nanchang University, Nanchang 330031, Jiangxi Province, China

Author contributions: Zhang YQ, Ding N, Zeng YF and Xiang YY contributed equally to this work, and they wrote the paper; Yang MW contributed to data collection and paper revision; Hong FF and Yang SL also contributed equally to this work, they are responsible for the idea, fund and the paper revision.

Supported by National Natural Science Foundation of China, No. 81260504, No. 81660151 and No. 81660751; Science Foundation of Science Commission of Jiangxi Province, No. 20161BBG70067; School Teaching Reform Fund of Nanchang University, No. NCUIGLX - 14-1-111.

Conflict-of-interest statement: There is no conflict of interest associated with any of the authors in this manuscript.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Shu-Long Yang, PhD, Professor, Department of Physiology, Basic Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, Jiangxi Province, China. slyang@ncu.edu.cn
Telephone: +86-791-86360556
Fax: +86-791-86360556

Received: December 6, 2016

Peer-review started: December 8, 2016
First decision: December 30, 2016
Revised: January 11, 2017
Accepted: February 16, 2017
Article in press: February 16, 2017
Published online: April 14, 2017

Abstract

Hepatic ischemia reperfusion injury (HIRI) is a clinical condition which may lead to cellular injury and organ dysfunction. The role of nitric oxide (NO) in HIRI is complicated and inconclusive. NO produced by endothelial nitric oxide synthase (eNOS) activation plays a protective role during early HIRI. But eNOS overexpression and the resulting excessive NO bioavailability can aggravate liver injury. NO induced by inducible nitric oxide synthase (iNOS) may have either a protective or a deleterious effect during the early phase of HIRI, but it may protect the liver during late HIRI. Here, we reviewed the latest findings on the role of NO during HIRI: (1) NO exerts a protective effect against HIRI by increasing NO bioavailability, downregulating p53 gene expression, decreasing inflammatory chemokines, reducing ROS via inhibiting the mitochondrial respiratory chain, activating sGC-GTP-cGMP signal pathway to reduce liver cell apoptosis, and regulating hepatic immune functions; (2) eNOS protects against HIRI by increasing NO levels, several eNOS/NO signal pathways (such as Akt-eNOS/NO, AMPK-eNOS/NO and HIF-1α-eNOS/NO) participating in the anti-HIRI process, and inhibiting over-expression of eNOS also protects against HIRI; and (3) the inhibition of iNOS prevents HIRI. Thus, the adverse effects of NO should be avoided, but its positive effect in the clinical treatment of diseases associated with HIRI should be recognized.

Key words: Liver; Hepatic ischemia reperfusion injury; Nitric oxide; Nitric oxide synthase
Core tip: The latest findings on the role of nitric oxide (NO) during hepatic ischemia reperfusion injury (HIRI) include: NO exerts a protective effect against HIRI by increasing NO bioavailability, downregulating p53 gene expression, decreasing inflammatory chemokines, reducing ROS by inhibiting the mitochondrial respiratory chain, activating sGC-GTP-cGMP signal pathway to reduce liver cell apoptosis, and regulating hepatic immune functions; eNOS protects against HIRI by increasing NO levels, several eNOS/NO signal pathways (such as Akt-eNOS/NO, AMPK-eNOS/NO and HIF-1α-eNOS/NO) participating in the anti-HIRI process; inhibiting over-expression of eNOS also protects against HIRI; and finally, the inhibition of iNOS prevented HIRI.


INTRODUCTION

Hepatic ischemia reperfusion injury (HIRI) is a clinical condition which may lead to cellular injury and organ dysfunction, mediated mainly through the production of reactive oxygen species and inflammatory cytokines[1]. Deterioration of hepatic homeostasis, as observed in IR, cold preservation and transplantation, septic organ failure, and hepatic resection-induced hyperperfusion, are associated with high rates of morbidity and mortality. It is well known that HIRI involves several mechanisms, which include pH imbalance, Ca²⁺ overload, mitochondrial damage induced by oxygen free radicals, endothelin (ET)/nitric oxide (NO) ratio imbalance, liver microcirculation dysfunction, activation of Kupffer cells and neutrophils, and the impact of various cytokines. During IR, there are interactions among liver cells, Kupffer cells, neutrophils, hepatic sinusoidal endothelial cells, and fat-storing cells. Platelets and alexin are also involved[2]. These activated cells release a large quantity of proinflammatory cytokine and lipid inflammatory factor, which can lead to inflammatory reaction and cell apoptosis.

NO is an unstable carbon-centered radical with a short half-life. There are two sources in organisms: one is non-enzymistgenes derived from the degradation or transformation of inorganic nitrogen chemicals in the body and food; and the other one is enzymistgenes, in which NO is produced in a redox reaction between L-arginine and oxygen molecules by NO synthase (NOS) catalyzation. There are three types of NOS: endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), and inducible nitric oxide synthase (iNOS). Endothelial nitric oxide synthase exists mainly in vascular endothelial cells while iNOS exists mainly in the cytoplasm of some inflammatory cells, such as white blood cells associated with diseases characterized by inflammation, tumors, and degeneration. NOS not only appears in soluble cytoplasm but also in some subcellular organelles. NO is produced mainly by eNOS catalysis, and also by the upregulation of iNOS expressions during acute hepatic ischemia[3]. It has been reported that iNOS is induced to produce large amounts of NO by lipopolysaccharide, interleukin-1 (IL-1), and tumor necrosis factor (TNF), which play a role in the pathophysiological process of some diseases and in many inflammation and immune reactions[4]. iNOS-derived NO may have either a protective or a deleterious effect during the early phase of IR injury, but it plays a protective role in the late phase of HIRI[5] (Table 1).

PROTECTIVE EFFECT OF NO DURING HIRI

NO was proved to reduce HIRI through various mechanisms[6,7], such as inhibiting liver cell apoptosis, slowing the infiltration of macrophages, eliminating superoxide anion produced by neutrophils, protecting the liver sinus structure and maintaining liver microcirculation blood flow, accelerating the liver tissue oxygenation, stabilizing ATP levels, decreasing oxidative stress injury, preventing the reduction of glutathione and the increase of endothelin side effects, and inhibiting platelet aggregation.

Increase of NO bioavailability involved in its protective effect in HIRI

In addition to NO donors, an increase in NO bioavailability can also protect the liver from HIRI. Human serum albumin (HSA) is a non-glycosylated protein, by which a series of recombinants, and mannosylated-HSA mutants (Man-rHSAs) are prepared; their triple mutant (TM-rHSA) can be selectively delivered to the liver via a mannose receptor on non-parenchymal liver cells, which can effectively deliver NO to the liver and have a significant inhibitory effect against HIRI[8].

NO downregulates the expression of the p53 gene and decreases inflammatory chemokines

During IR, NO donors may decrease p53 gene expression and the levels of IL-1 and TNF-α as well as inhibit cell apoptosis to protect the heart, liver, lungs, and kidneys from IR injury. Elevated NO levels can inhibit p53 gene expression and decrease the production of proinflammatory cytokines and chemokines, such as intercellular adhesion molecule (ICAM), TNF-α, IL-1, MIP-1, and MIP-2. In particular, lower levels of ICAM,
April 14, 2017 | Volume 23 | Issue 14 | WJG | www.wjgnet.com

Table 1  Roles of nitric oxide, endothelial nitric oxide synthase and inducible nitric oxide synthase in pharmacological protection against hepatic ischemia reperfusion injury

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>NO/iNOS/eNOS levels</th>
<th>Animals</th>
<th>Experimental cells</th>
<th>Mechanism</th>
<th>Liver cell necrosis and liver damage</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-arginine and HIRI</td>
<td>NO↑</td>
<td>Male Sprague-Dawley rats</td>
<td>Hepatocytes</td>
<td>O2-, NO2-/NO3- concentration↑</td>
<td>↓</td>
<td>[6]</td>
</tr>
<tr>
<td>L-NAME and HIRI</td>
<td>NO↑</td>
<td>Male Sprague-Dawley rats</td>
<td>Liver cells</td>
<td>NO2-/NO3- concentration↑</td>
<td>↑</td>
<td>[7]</td>
</tr>
<tr>
<td>Human serum albumin↑</td>
<td>NO↑</td>
<td>Rats underwent liver transplant</td>
<td>Liver parenchyma</td>
<td>Man-rHSA↑</td>
<td>↓</td>
<td>[8]</td>
</tr>
<tr>
<td>SNAP and HIRI</td>
<td>NO↑</td>
<td>Vein endothelial cells</td>
<td>Various cell types</td>
<td>Cytochrome oxidase, oxygen radical↑</td>
<td>↓</td>
<td>[9,10]</td>
</tr>
<tr>
<td>Nitrates and hypoxia/ reoxygenation</td>
<td>NO↑</td>
<td>Trachemys Acripta elegans</td>
<td>Liver cells</td>
<td>sGC, cGMP, PKG, PI3K, V-ATPase ↑, intracellular Na+, H+↓</td>
<td>↓</td>
<td>[5]</td>
</tr>
<tr>
<td>L-arginine and HIRI</td>
<td>NO↑</td>
<td>Liver cells</td>
<td>Intracellular Na+, H+, PKC, Ca2+↑</td>
<td></td>
<td>↓</td>
<td>[14,15]</td>
</tr>
<tr>
<td>HIRI</td>
<td>eNOS,NO↑</td>
<td>Bovine aortic endothelial cells and COS-7 cells</td>
<td></td>
<td>Intracellular Na+, H+, PKC, Ca2+↑</td>
<td>↓</td>
<td>[16,17]</td>
</tr>
<tr>
<td>rHuEPO and HIRI</td>
<td>NO↑</td>
<td>Adult male Sprague-Dawley rats</td>
<td>Liver cells</td>
<td>PI3K/Akt/eNOS pathway</td>
<td>↓</td>
<td>[18]</td>
</tr>
<tr>
<td>Institut Georges Lopez-1 and HIRI</td>
<td>eNOS↑</td>
<td>Adult male SD rats</td>
<td>Liver cells</td>
<td>Akt,AMPK↑</td>
<td>↓</td>
<td>[19]</td>
</tr>
<tr>
<td>Adiponectin and HIRI</td>
<td>eNOS↑</td>
<td>Adult male Wistar rats</td>
<td>Hepatocytes</td>
<td>AMPK/eNOS pathway</td>
<td>↓</td>
<td>[20]</td>
</tr>
<tr>
<td>Heparin cofactor II and ischemia</td>
<td>eNOS↑</td>
<td>Male heterozygote HC II deficient mice and male littermate</td>
<td>Vascular endothelial cell</td>
<td>AMPK/eNOS signaling pathway</td>
<td>↓</td>
<td>[21]</td>
</tr>
<tr>
<td>Triptazinidine, IGL-1, and HIRI</td>
<td>eNOS,NO↑</td>
<td>Isolated perfused livers rats model</td>
<td>Steatotic and non-steatotic livers cells</td>
<td>HIF-1α, heme-oxygenase-1↑</td>
<td>↓</td>
<td>[22]</td>
</tr>
<tr>
<td>Knockdown of AK13928 and HIRI</td>
<td>eNOS↑</td>
<td>Mice</td>
<td>Liver cells</td>
<td>p-eNOS, p-Akt, PGSK-3 ↑, macrophage infiltration, NF-κB↓</td>
<td>↓</td>
<td>[23]</td>
</tr>
<tr>
<td>Ad-eNOS and HIRI</td>
<td>eNOS↑</td>
<td>Male inbred C57BL/6 lean mice</td>
<td>Liver cells</td>
<td>ATP↓, bax↑</td>
<td>↑</td>
<td>[24]</td>
</tr>
<tr>
<td>Rosmarinic acid and HIRI</td>
<td>eNOS,NO,N↓</td>
<td>Mice</td>
<td>Liver</td>
<td>GSH↑</td>
<td></td>
<td>[25]</td>
</tr>
<tr>
<td>Riboflavin and HIRI</td>
<td>eNOS,NO,N↓</td>
<td>Rats</td>
<td>Liver</td>
<td>eNOS excessive expression↑, NF-κB activity, TNF-α and IL-1β gene expression↑</td>
<td>↓</td>
<td>[26]</td>
</tr>
<tr>
<td>Alpha lipoic acid and HIRI</td>
<td>iNOS,N↓</td>
<td>Male Wistar strain rats</td>
<td>Hepatocytes</td>
<td>iNOS mRNA stability ↓</td>
<td>↓</td>
<td>[31]</td>
</tr>
</tbody>
</table>

<: No data; Man-rHSA: Mannosylated-HSA mutants; HIRI: Hepatic ischemia reperfusion injury; IGL-1: Institut georges lopez-1; SNAP: S-nitroso-N-acetylpenicillamine; ICAM: Intercellular adhesion molecule; Akt: Protein kinase B; AMPK: Adenosine monophosphate-activated protein kinase; TNF-α: Tumor necrosis factor-α; NF-κB: Nuclear factor-κB gene binding; ERK: Extracellular regulated protein kinase; JNK: Jun N-terminal kinase; P38K: Phosphoinositide 3-kinase; V-ATPase: Vacuolar H+-ATPase; rHuEPO: Recombinant human erythropoietin; HIF-1α: Hypoxia inducible factor 1α; PGSK-3: Phosphorylated glycogen synthase kinase 3; eNOS: Endothelial nitric oxide synthase; iNOS: Inducible nitric oxide synthase.

MIP-1, and MIP-2 are accompanied by less neutrophil infiltration[9,10]. The application of ICAM-1 monocolonal antibody 1A29F is likely to provide a more effective treatment for primary grafted liver dysfunction[11]. NO can also reduce the level of TNF-α to inhibit NF-κB. Decreased NF-κB can inhibit MAPKs, including p38, ERK, and JNK. A reduced p38 level can lead to the inhibition of caspase-3 and gene p53 expression. Thus, the downregulation of p53, ERK and JNK results in reduction of cell inflammation[11].

**NO reduces ROS by inhibiting the mitochondrial respiratory chain**

Using transgenic knockout rats, Datta studied the molecular mechanism of HIRI. It was found that the initial liver injury is initiated by reactive oxygen species, which cause direct cellular injury and also activate a cascade of molecular mediators, leading to microvascular changes, increased apoptosis, and acute inflammatory changes with increased hepatocyte necrosis. However, during the period of reperfusion, some adaptive changes occur in order to reduce HIRI[12]. Exogenously administered NO donors can inhibit the oxidation of mitochondrial cytochrome and reduce ROS production. Excessive ROS is generated in liver cells after its hypoxia/reoxygenation, which causes protein oxidation and lipid peroxidation. Hence, NO reduces ROS production by inhibiting...
mitochondrial respiratory chain complexes[13].

**NO activates sGC-GTP-cGMP signaling pathway to reduce liver cell apoptosis**

NO derived from blood vessels can activate soluble guanylyl cyclase (sGC), catalyzing guanosine triphosphate (GTP) to produce cyclic 3′, 5′ guanosine monophosphate (cGMP). The protection of cGMP-dependent protein kinase (PKG) activated by cGMP results in the activation of PI3K and the phosphorylation of p38 MAPK, leading to the activation of vacuolar H^+-ATPases (V-ATPases), which lead to the extrusion of [H^+] ([H^+]i) from the cytosol of hepatocytes into the extracellular environment, thereby resulting in inhibition of the H^+-driven Na^+/H^+ exchanger (NHE) and Na^+/HCO_3 cotransporter (NHCT), with a consequent reduction in [Na^+] (Na^+)) and protection from hepatocyte death[5]. Diao et al[11] observed that NO plays an important protective role in organ preservation by supplementing sufficient NO donors to enhance the NO/cGMP pathway.

**NO regulates hepatic immune function**

NO is also an important effector molecule that is involved in immune regulation and host innate and acquired immunity. NO inhibits proinflammatory cytokines, including TNF-α, IL-1β, IL-1α, and IL-12, which may induce the inflammatory cascade during HIRI. In addition, NO can decrease the number of T helper 1 (Th1) cells and promote the proliferation of Th2 cells, regulate leukocyte adhesion, and induce the generation of T regulatory (Treg) cells[14,15].

It has also been reported that excessive NO may paradoxically damage liver tissue by forming nitrogen peroxide, indicating that the dose of exogenous NO donors is vital to HIRI therapy.

**ENOS CONTRIBUTES TO PROTECTIVE FUNCTIONS AGAINST HIRI**

**ENOS activation increases NO levels**

Intracellular Ca^{2+} levels are the key factors that activate eNOS. During HIRI, Na^+/Ca^{2+} exchange protein on the cell membrane is activated directly or indirectly by the high concentration of Na^+, H^+, and PKC, leading to an increase in intracellular Ca^{2+}. Furthermore, with the liver cell membrane structure damaged, Ca^{2+} transports into the cellular membrane increased, and the endoplasmic reticulum and sarcoplasmic reticulum are also destroyed, which inhibits the function of the calcium pump to elevate the intracellular Ca^{2+} concentration. Meanwhile, stored intracellular Ca^{2+} is released. All these may lead to a higher intracellular Ca^{2+} concentration, which activates eNOS to produce more NO[16,17]. The basic low-dose NO catalyzed by eNOS could mitigate the hepatic microcirculation pressure caused by reperfusion.

**ENOS/NO SIGNALING PATHWAYS PARTICIPATE IN ANTI-HIRI ACTIVITY**

**Akt-eNOS/NO pathway**

PI3K is a heterodimer composed of the catalytic subunit p105 and regulatory subunit p85, and is also a lipid second messenger. PI3K can phosphorylate the serine/threonine of its downstream signal kinase Akt, which may further phosphorylate eNOS to promote an increase in endogenous NO generation. The protective effect of rHuEPO in IR injury is mediated via the activation of the PI3K/Akt/eNOS signaling pathway, at least in part, by increasing p-AKT and p-eNOS, which leads to the maintenance of an elevated level of NO[18]. It has been reported that IGL-1 solution results in better liver preservation and protection against HIRI by activating Akt and AMPK, which are concomitant with increased eNOS expression and nitrite/nitrate levels[19].

**AMPK-eNOS/NO pathway**

Zhang C reported that adiponectin (APN) can protect the liver from HIRI by reducing the inflammatory reaction and hepatocyte apoptosis, the process that likely involves the AMPK/eNOS pathway[20]. In addition, heparin cofactors II (HCII) potentiates hepatic vascular endothelial cell activity and the promotion of angiogenesis via an AMPK/eNOS signaling pathway to decrease vascular injury[21].

**HIF-1α-eNOS/NO pathway**

Adding trimetazidine, an anti-ischemia drug, to IGL-1 induces NO and eNOS activation. In normoxic reperfusion, the presence of NO favors hypoxia-inducible factor-1α (HIF-1α) accumulation, and also promotes the activation of other cytoprotective genes to reduce HIRI, such as heme-oxygenase-1. In addition, NO could reduce HIRI via the HIF-1α/NO pathway[22].

**Other new pathways**

Deregulated long noncoding RNA (LncRNAs) AK139328 is involved in HIRI. In the IR liver, the knockdown of AK139328 increases survival-signaling proteins including phosphorylated Akt (pAkt), glycogen synthase kinase 3 (pGSK3), and endothelial nitric oxide synthase (peNOS). Furthermore, the knockdown of AK139328 also reduces macrophage infiltration and inhibits NF-κB activity and inflammatory cytokine expression[23]. This could provide some new options for the diagnosis and treatment of liver diseases, such as surgery or transplantation.

**Inhibition of eNOS overexpression to protect HIRI**

The most current evidence supports the idea that the overexpression of eNOS is detrimental in the setting of hepatic IR[24]. Sanches SC found that during HIRI, the riboflavin infusion partially recovered hepatic GSH reserves and decreased eNOS/iNOS and NO levels in.
the liver, and that riboflavin could have antioxidant and anti-inflammatory effects in the ischemic liver, protecting hepatocytes against IR injury.\textsuperscript{[25]}

Rosmarinic acid, which is a kind of water-soluble phenolic acid compound and a natural antioxidant, has many biological functions, such as antibacterial, antiviral, and anti-inflammatory effects, prevention of high calcium concentrations in the cell, and regulation of immune function. Also, it could inhibit eNOS overexpression in the liver; decrease eNOS/iNOS and NO levels in the liver; attenuate NF-\(\kappa\)B activation, downregulate TNF-\(\alpha\) and IL-1\(\beta\) gene expression, and exert anti-inflammatory and antioxidant effects in the ischemic liver, thereby protecting hepatocytes against IRI.\textsuperscript{[26]}

\textbf{ROLE OF INOS IN HIRI}

During sudden hepatic ischemic stress, upregulated iNOS in the liver produces a large quantity of NO as a response. However, up-regulating the expressions of iNOS gene and protein requires time.\textsuperscript{[7]}

\textbf{iNOS aggravates HIRI}

Some evidence suggests that eNOS can lead to “dysfunction” during oxidative stress, so production of a large amount of NO against IRI appears to be necessary for the expression of iNOS.\textsuperscript{[27,28]} Hu et al\textsuperscript{[29]} discovered that while the expression of iNOS mRNA peaked 3 h after hepatic reperfusion, the highest protein level appeared after 6 h. After 4 h of reperfusion, the increased iNOS mRNA transcription did not result in increased NO production, and this lack of increase may be linked to different degrees of tissue damage.\textsuperscript{[30]}

\textit{Inhibition of iNOS prevented liver from HIRI}

Alpha lipoic acid (\(\alpha\)-LA) has been shown to alleviate HIRI in rats. The underlying mechanism may be that \(\alpha\)-LA inhibits the expression of the iNOS gene antisense-transcript, which is involved in iNOS mRNA stability. Therefore, there may be useful therapeutic effects associated with the suppression of iNOS induction involved in liver injury.\textsuperscript{[31]}

IL-1\(\beta\) and TNF-\(\alpha\) are important proinflammatory cytokines.\textsuperscript{[14]} The upregulation of IL-1\(\beta\) receptors accelerates the iNOS transcription process, but the mechanism involved in its downstream signaling pathway is unknown.\textsuperscript{[32]} Blocking IL-1 receptors may be a way to alleviate HIRI. Although it is uncertain whether the reduction of IL-1 receptors is related to iNOS transcription, it does show that iNOS is involved in the process.\textsuperscript{[33]}

\textbf{CONCLUSION}

NO plays a complicated role during HIRI. NO can inhibit the expression of p53 gene and the aggregation of proinflammatory cytokines and chemokines, reduce ROS by inhibiting the mitochondrial respiratory chain, participate in hepatic immune modulation, inhibit the inflammatory cascade, and exhibit anti-inflammatory properties. In addition, as the first messenger, NO activated the NO/cGMP pathway to inhibit \([\text{Na}^+]/\text{K}^+\) from entering the cells, thereby helping to maintain hepatic cell integrity. Conversely, excessive NO in serum can aggravate liver injury. Elevating NO levels appropriately, such as by applying exogenous NO donors or increasing NO availability in the liver, may be a good way to prevent and treat HIRI. There are two ways to activate eNOS which can promote an increase in endogenous NO generation to protect liver tissue from HIRI. One is elevating Ca\(^{2+}\) levels in cells or phosphorylating the active site of eNOS gene, and the other is knocking out gene AK139328. Both can protect the liver from HIRI. But excessive NO levels derived from eNOS are detrimental to the liver. iNOS has a synergistic effect with some inflammatory mediators, which cause cellular swelling and apoptosis. Excessive NO derived from iNOS plays a protective role in the late period of HIRI. Thus, adverse effects of NO should be avoided, and its positive effects in the clinical treatment of diseases associated with HIRI should be recognized.

\textbf{REFERENCES}


P- Reviewer: Nerri V  S- Editor: Ma YJ  L- Editor: Ma YJ  E- Editor: Wang CH